Logo image of ROIV

ROIVANT SCIENCES LTD (ROIV) Stock Fundamental Analysis

NASDAQ:ROIV - Nasdaq - BMG762791017 - Common Stock - Currency: USD

10.68  -0.04 (-0.37%)

After market: 10.68 0 (0%)

Fundamental Rating

4

ROIV gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ROIV as it has an excellent financial health rating, but there are worries on the profitability. ROIV is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ROIV has reported negative net income.
ROIV had a negative operating cash flow in the past year.
In multiple years ROIV reported negative net income over the last 5 years.
In the past 5 years ROIV always reported negative operating cash flow.
ROIV Yearly Net Income VS EBIT VS OCF VS FCFROIV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 1B -1B 2B 3B 4B

1.2 Ratios

The Return On Assets of ROIV (-2.01%) is better than 91.30% of its industry peers.
With an excellent Return On Equity value of -2.25%, ROIV belongs to the best of the industry, outperforming 92.72% of the companies in the same industry.
Industry RankSector Rank
ROA -2.01%
ROE -2.25%
ROIC N/A
ROA(3y)-4.9%
ROA(5y)-0.13%
ROE(3y)-21.77%
ROE(5y)-11.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROIV Yearly ROA, ROE, ROICROIV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

Looking at the Gross Margin, with a value of 89.85%, ROIV belongs to the top of the industry, outperforming 93.07% of the companies in the same industry.
In the last couple of years the Gross Margin of ROIV has remained more or less at the same level.
ROIV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.85%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.41%
GM growth 5YN/A
ROIV Yearly Profit, Operating, Gross MarginsROIV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 2K -2K -4K

More info and screens

8

2. Health

2.1 Basic Checks

ROIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ROIV has been increased compared to 1 year ago.
ROIV has a better debt/assets ratio than last year.
ROIV Yearly Shares OutstandingROIV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 200M 400M 600M 800M
ROIV Yearly Total Debt VS Total AssetsROIV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

ROIV has an Altman-Z score of 8.19. This indicates that ROIV is financially healthy and has little risk of bankruptcy at the moment.
ROIV has a Altman-Z score of 8.19. This is amongst the best in the industry. ROIV outperforms 85.26% of its industry peers.
ROIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.19
ROIC/WACCN/A
WACC8.7%
ROIV Yearly LT Debt VS Equity VS FCFROIV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

ROIV has a Current Ratio of 37.91. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 37.91, ROIV belongs to the top of the industry, outperforming 98.76% of the companies in the same industry.
A Quick Ratio of 37.91 indicates that ROIV has no problem at all paying its short term obligations.
The Quick ratio of ROIV (37.91) is better than 98.76% of its industry peers.
Industry RankSector Rank
Current Ratio 37.91
Quick Ratio 37.91
ROIV Yearly Current Assets VS Current LiabilitesROIV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

6

3. Growth

3.1 Past

ROIV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.28%, which is quite impressive.
Looking at the last year, ROIV shows a very negative growth in Revenue. The Revenue has decreased by -59.09% in the last year.
Measured over the past years, ROIV shows a very strong growth in Revenue. The Revenue has been growing by 73.73% on average per year.
EPS 1Y (TTM)88.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%176.67%
Revenue 1Y (TTM)-59.09%
Revenue growth 3Y73.73%
Revenue growth 5YN/A
Sales Q2Q%-75.74%

3.2 Future

ROIV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.59% yearly.
ROIV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 68.30% yearly.
EPS Next Y55.02%
EPS Next 2Y2.52%
EPS Next 3Y2.64%
EPS Next 5Y18.59%
Revenue Next Year-34.63%
Revenue Next 2Y-55.9%
Revenue Next 3Y-22.27%
Revenue Next 5Y68.3%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ROIV Yearly Revenue VS EstimatesROIV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
ROIV Yearly EPS VS EstimatesROIV Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ROIV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ROIV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ROIV Price Earnings VS Forward Price EarningsROIV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ROIV Per share dataROIV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.52%
EPS Next 3Y2.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ROIV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROIVANT SCIENCES LTD

NASDAQ:ROIV (2/21/2025, 8:00:01 PM)

After market: 10.68 0 (0%)

10.68

-0.04 (-0.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10 2025-02-10/bmo
Earnings (Next)N/A N/A
Inst Owners69.81%
Inst Owner ChangeN/A
Ins Owners7.28%
Ins Owner Change-10.52%
Market Cap7.62B
Analysts85
Price Target17.19 (60.96%)
Short Float %9.59%
Short Ratio9.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)80.76%
Min EPS beat(2)-18.6%
Max EPS beat(2)180.12%
EPS beat(4)3
Avg EPS beat(4)86.34%
Min EPS beat(4)-18.6%
Max EPS beat(4)180.12%
EPS beat(8)5
Avg EPS beat(8)43.36%
EPS beat(12)7
Avg EPS beat(12)24.66%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-67.92%
Min Revenue beat(2)-91.09%
Max Revenue beat(2)-44.75%
Revenue beat(4)1
Avg Revenue beat(4)-18.56%
Min Revenue beat(4)-91.09%
Max Revenue beat(4)71.59%
Revenue beat(8)4
Avg Revenue beat(8)-2.03%
Revenue beat(12)6
Avg Revenue beat(12)0.59%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.42%
PT rev (3m)0.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.25%
EPS NY rev (1m)23.46%
EPS NY rev (3m)22.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-57.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-21.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 151.17
P/FCF N/A
P/OCF N/A
P/B 1.47
P/tB 1.47
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.09
OCFYN/A
SpS0.07
BVpS7.27
TBVpS7.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.01%
ROE -2.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.85%
FCFM N/A
ROA(3y)-4.9%
ROA(5y)-0.13%
ROE(3y)-21.77%
ROE(5y)-11.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.41%
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.15%
Cap/Sales 8.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 37.91
Quick Ratio 37.91
Altman-Z 8.19
F-Score4
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%176.67%
EPS Next Y55.02%
EPS Next 2Y2.52%
EPS Next 3Y2.64%
EPS Next 5Y18.59%
Revenue 1Y (TTM)-59.09%
Revenue growth 3Y73.73%
Revenue growth 5YN/A
Sales Q2Q%-75.74%
Revenue Next Year-34.63%
Revenue Next 2Y-55.9%
Revenue Next 3Y-22.27%
Revenue Next 5Y68.3%
EBIT growth 1Y-1.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-580.36%
EBIT Next 3Y-92.69%
EBIT Next 5YN/A
FCF growth 1Y5.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.48%
OCF growth 3YN/A
OCF growth 5YN/A